15.87
2.10%
-0.34
Tyra Biosciences Inc stock is traded at $15.87, with a volume of 253.12K.
It is down -2.10% in the last 24 hours and down -41.93% over the past month.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
See More
Previous Close:
$16.21
Open:
$16.18
24h Volume:
253.12K
Relative Volume:
0.81
Market Cap:
$803.07M
Revenue:
-
Net Income/Loss:
$-69.13M
P/E Ratio:
-13.22
EPS:
-1.2
Net Cash Flow:
$-50.91M
1W Performance:
+0.83%
1M Performance:
-41.93%
6M Performance:
-15.22%
1Y Performance:
+40.82%
Tyra Biosciences Inc Stock (TYRA) Company Profile
Name
Tyra Biosciences Inc
Sector
Industry
Phone
(619) 728-4760
Address
2656 STATE STREET, CARLSBAD
Compare TYRA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
TYRA | 15.87 | 803.07M | 0 | -69.13M | -50.91M | -1.20 |
VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-30-23 | Initiated | Wedbush | Outperform |
Feb-03-23 | Initiated | Oppenheimer | Outperform |
Jun-23-22 | Initiated | H.C. Wainwright | Buy |
Mar-08-22 | Upgrade | Jefferies | Hold → Buy |
Nov-08-21 | Downgrade | Jefferies | Buy → Hold |
Oct-11-21 | Initiated | BofA Securities | Buy |
Oct-11-21 | Initiated | Cowen | Outperform |
Oct-11-21 | Initiated | Jefferies | Buy |
View All
Tyra Biosciences Inc Stock (TYRA) Latest News
How to Take Advantage of moves in (TYRA) - Stock Traders Daily
Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 5%Here's Why - MarketBeat
Short Interest in Tyra Biosciences, Inc. (NASDAQ:TYRA) Drops By 20.0% - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Shares Gap UpWhat's Next? - MarketBeat
RA Capital Management, L.P. Increases Stake in Tyra Biosciences Inc - GuruFocus.com
Tyra Biosciences to Present FGFR Precision Medicine Updates at Major Healthcare Conferences | TYRA Stock News - StockTitan
Equities Analysts Offer Predictions for TYRA FY2024 Earnings - MarketBeat
FMR LLC Increases Stake in Tyra Biosciences Inc - GuruFocus.com
Tyra Biosciences stock target cut, retains buy rating on clinical data - Investing.com Canada
HC Wainwright Has Lowered Expectations for Tyra Biosciences (NASDAQ:TYRA) Stock Price - MarketBeat
Tyra Biosciences director Nina Kjellson sells $1.28 million in stock By Investing.com - Investing.com Australia
Tyra Biosciences’ Q3 2024: Clinical Progress and Financial Resilience - TipRanks
Tyra Biosciences director Nina Kjellson sells $1.28 million in stock - Investing.com
Tyra Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights - PR Newswire
Tyra Biosciences director Nina S. Kjellson sells shares worth $194k - Investing.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Sold by Auour Investments LLC - MarketBeat
Long Term Trading Analysis for (TYRA) - Stock Traders Daily
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up After Insider Buying Activity - MarketBeat
Tyra Biosciences director Nina Kjellson sells $2.28m in stock By Investing.com - Investing.com Australia
Tyra Biosciences director Nina Kjellson sells $2.28m in stock - Investing.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) CFO Purchases $152,000.00 in Stock - MarketBeat
Tyra Biosciences CFO Alan Fuhrman acquires $151,954 in stock By Investing.com - Investing.com South Africa
Tyra Biosciences CFO Alan Fuhrman acquires $151,954 in stock - Investing.com
Tyra Biosciences (NASDAQ:TYRA) Trading Down 10.2%Here's What Happened - MarketBeat
Tyra Biosciences advances with Phase 2 trial for achondroplasia treatment By Investing.com - Investing.com Australia
Tyra Biosciences advances with Phase 2 trial for achondroplasia treatment - Investing.com
Piper Sandler maintains Overweight on Tyra Biosciences stock By Investing.com - Investing.com Canada
Tyra Biosciences stock target lifted, retains buy on clinical trial data - Investing.com Canada
Tyra Biosciences (NASDAQ:TYRA) Sees Strong Trading Volume on Analyst Upgrade - MarketBeat
FDA clears Tyra Biosciences' trial for dwarfism drug By Investing.com - Investing.com Australia
Tyra Biosciences (NASDAQ:TYRA) Price Target Raised to $32.00 at HC Wainwright - MarketBeat
FDA clears Tyra Biosciences' trial for dwarfism drug - Investing.com India
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) - PR Newswire
Tyra Biosciences (NASDAQ:TYRA) Shares Gap DownWhat's Next? - MarketBeat
Tyra Biosciences' (TYRA) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday? - Benzinga
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer - Marketscreener.com
(TYRA) Long Term Investment Analysis - Stock Traders Daily
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) - PR Newswire
Wall Street Analysts Think Tyra Biosciences (TYRA) Could Surge 27.88%: Read This Before Placing a Bet - MSN
Tyra Biosciences (NASDAQ:TYRA) Sets New 52-Week HighWhat's Next? - MarketBeat
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET - Marketscreener.com
Tyra Biosciences stock soars to 52-week high of $28.86 - Investing.com India
Tyra Biosciences stock soars to 52-week high of $28.86 By Investing.com - Investing.com South Africa
RA Capital Management, L.P. Reduces Stake in Tyra Biosciences Inc - Yahoo Finance
Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells 19,084 Shares of Stock - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Shares Up 4.2%Here's Why - MarketBeat
Tyra Biosciences Inc Stock (TYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):